Alnylam : Phase 3 HELIOS-B Study Shows Vutrisiran Reduces Cardiovascular Events In ATTR-CM
17/5 14:36
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that results from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) demonstrate that the drug effectively reduces key cardiovascular (CV) events, includ...